BioCentury
ARTICLE | Company News

Clovis, Ethical Oncology Science deal

November 25, 2013 8:00 AM UTC

Clovis acquired Ethical Oncology Science for $200 million up front - including $10 million in cash and about 3.7 million shares of Clovis stock - plus up to $220 million in milestones. Clovis gains lucitanib ( E-3810), which is in a Phase I/IIa trial for solid tumors. EOS has ex-Chinese rights to the small molecule inhibitor of fibroblast growth factor (FGF) receptor 1 ( FGFR1) and VEGF from Advenchen Laboratories LLC (Moorpark, Calif.).

Clovis and Servier (Neuilly-sur-Seine, France) - which has exclusive rights from EOS to lucitanib outside of the U.S., Japan and China under a September 2012 deal - will develop lucitanib together. Clovis is eligible for up to €350 million ($472.6 million) in milestones from Servier, plus low- to mid-teen double-digit royalties on lucitanib sales (see BioCentury, Oct. 8, 2012). ...